Table 3 Metaregression of included studies
Study characteristics | Prevalence of high risk (%, 95% CI) | P value | Prevalence of moderate risk (%, 95% CI) | P value |
|---|---|---|---|---|
All studies | 13.8 (10.9,16.8) | 19.9 (16.8,23.1) | ||
Sample type | ||||
Population survey | 13.5 (8.8,18.1) | 0.86 | 18.7 (14.3,23.1) | 0.47 |
Community sample | 14.0 (10.2,17.8) | 21.0 (16.7,25.2) | ||
Type of PEDS | ||||
Survey PEDS | 17.9 (10.9,24.9) | 0.15 | 20.6 (16.9,24.3) | 0.50 |
Clinical PEDS | 12.6(9.6,15.7) | 18.3 (12.9,23.7) | ||
Study purpose | ||||
Population risk measure | 14.5 (9.7,19.2) | 0.71 | 20.1 (15.4,24.9) | 0.92 |
Developmental surveillance tool | 13.3 (9.6,17.1) | 19.8 (15.6,24.0) | ||
Study quality | ||||
High quality | 13.5 (8.8,18.1) | 0.86 | 18.7 (14.3,23.1) | 0.47 |
Medium/low quality | 14.0 (10.2,17.8) | 21.0 (16.7,25.2) | ||
Study age group | ||||
3 years and under | 14.5(8.9,20.2) | 0.76 | 22.9(16.7,29.1) | 0.25 |
Includes over 3 years | 13.5(10.1,16.9) | 18.9 (15.4,22.3) | ||
Publication type | ||||
Peer review/Government report | 11(8.1,14.0) | 0.013 | 21.1(16.9,24.4) | 0.39 |
Abstracts/website/manuals | 18.0(13.0,22.9) | 18.4(14.1,22.8) | ||
Country income | High | |||
High | 13.2(10.2,16.3) | 0.38 | 21.5(18.6,24.5) | 0.001 |
Middle/low | 17.2(8.2,26.1) | 8.4(3.7,13.1) |